Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis

Basile, Christian; Paolillo, Stefania; Gargiulo, Paola; Marzano, Federica; Asile, Gaetano; Parlati, Antonio Luca Maria; Chirico, Alfonsina; Nardi, Ermanno; Buonocore, Davide; Colella, Angela; Perrone‐Filardi, Pasquale

doi:10.2459/jcm.0000000000001411

Cited by 8 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can decrease mortality and the risk of hospitalization in patients with HF. [9,10] Liver dysfunction is prevalent in HF patients, so there has been growing interest in the relationship between the heart and the liver in HF. [11] Sacubitril/valsartan improves measures of liver function compared with enalapril.…”

Section: Discussionmentioning

confidence: 99%

Sacubitril/valsartan-induced liver injury: A case report and literature review

Zhang

Cai

2023

Medicine

View full text Add to dashboard Cite

Rationale: Sacubitril/valsartan (Entresto) is the first drug approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adult patients. There have been no reports of hepatotoxicity secondary to sacubitril/valsartan administration. Here, we report the first case of severe liver injury caused by sacubitril/valsartan. Patient concerns: A 90-year-old female patient taking sacubitril/valsartan was admitted due to chronic heart failure. Subsequently, the patient developed serious liver injury with increased hepatic transaminases. Diagnosis: Drug-induced liver injury, sacubitril/valsartan-related. No liver injury caused by other reasons was observed after thorough examination. After the withdrawal of sacubitril/valsartan, the liver function of the patient gradually returned to normal. Interventions: We chose general liver protection methods to improve her hepatic function, including magnesium isoglycyrrhizinate at 100 mg daily and polyene phosphatidylcholine capsules at 456 mg 3 times daily. We consulted with a hepatologist to discuss the best plan for her treatment. The last, we stopped sacubitril/valsartan. Outcomes: After the withdrawal of sacubitril/valsartan, the liver function of the patient gradually returned to normal. Lessons: Sacubitril/valsartan-induced liver injury is very rare. Clinicians should pay particular attention to the possibility of hepatotoxicity during sacubitril/valsartan treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Sacubitril/valsartan-induced liver injury: A case report and literature review

Zhang

Cai

2023

Medicine

View full text Add to dashboard Cite

show abstract

“…How important the duration of HF is has been evaluated in a recently published post hoc analysis of PARAGON-HF RCT [ 112 ], which reported that the longer the HF duration was, the higher the risk of HFH in the absence of significant variations in the effects of sacubitril/valsartan. Moreover, the highest benefit was reported in those subjects with long-standing HF.…”

Section: Evidence-based Medicine: Appropriateness Of Treatment and Pa...mentioning

confidence: 99%

Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon

Lucà,

Oliva,

Abrignani

et al. 2024

JCM

View full text Add to dashboard Cite

Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable heterogeneity in both phenotypic and pathophysiological features, with a growing incidence due to the increase in median age and comorbidities such as obesity, arterial hypertension, and cardiometabolic disease. In recent decades, the development of new pharmacological and non-pharmacological options has significantly impacted outcomes, improving clinical status and reducing mortality. Moreover, a more personalized and accurate therapeutic management has been demonstrated to enhance the quality of life, diminish hospitalizations, and improve overall survival. Therefore, assessing the peculiarities of patients with HFpEF is crucial in order to obtain a better understanding of this disorder. Importantly, comorbidities have been shown to influence symptoms and prognosis, and, consequently, they should be carefully addressed. In this sense, it is mandatory to join forces with a multidisciplinary team in order to achieve high-quality care. However, HFpEF remains largely under-recognized and under-treated in clinical practice, and the diagnostic and therapeutic management of these patients remains challenging. The aim of this paper is to articulate a pragmatic approach for patients with HFpEF focusing on the etiology, diagnosis, and treatment of HFpEF.

show abstract

“…More recently sodium glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated efficacy in treatment of HFpEF reducing morbidity and mortality [ 7 ]. Moreover, recent meta-analysis including patients with HFpEF supports the beneficial effect of neurohormonal inhibitors, ACE inhibitors, angiotensin receptor inhibitors, and angiotensin receptor/neprilysin inhibitor (ARNi) on a composite outcome of death and HF hospitalizations [ 8 , 9 ].…”

Section: Epidemiologymentioning

confidence: 99%

Novel Strategies in Diagnosing Heart Failure with Preserved Ejection Fraction: A Comprehensive Literature Review

Mancusi,

Basile,

Spaccarotella

et al. 2024

High Blood Press Cardiovasc Prev

Self Cite

View full text Add to dashboard Cite

Heart failure (HF) with preserved ejection fraction (HFpEF) is a prevalent global condition affecting approximately 50% of the HF population. With the aging of the worldwide population, its incidence and prevalence are expected to rise even further. Unfortunately, until recently, no effective medications were available to reduce the high mortality and hospitalization rates associated with HFpEF, making it a significant unmet need in cardiovascular medicine. Although HFpEF is commonly defined as HF with normal ejection fraction and elevated left ventricular filling pressure, performing invasive hemodynamic assessments on every individual suspected of having HFpEF is neither feasible nor practical. Consequently, several clinical criteria and diagnostic tools have been proposed to aid in diagnosing HFpEF. Overall, these criteria and tools are designed to assist healthcare professionals in identifying and evaluating patients who may have HFpEF based on a combination of signs, symptoms, biomarkers, and non-invasive imaging findings. By employing these non-invasive diagnostic approaches, clinicians can make informed decisions regarding the best pharmacological and rehabilitation strategies for individuals with suspected HFpEF. This literature review aims to provide an overview of all currently available methods for diagnosing and monitoring this disabling condition.

show abstract

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis

Cited by 8 publications

References 25 publications

Sacubitril/valsartan-induced liver injury: A case report and literature review

Sacubitril/valsartan-induced liver injury: A case report and literature review

Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon

Novel Strategies in Diagnosing Heart Failure with Preserved Ejection Fraction: A Comprehensive Literature Review

Contact Info

Product

Resources

About